Maxim Group set a $14.00 target price on Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on the company. HC Wainwright lifted their price objective on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a buy rating in a report on Monday, February 12th. ValuEngine cut Galmed Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, February 14th. Finally, Zacks Investment Research raised Galmed Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price objective for the company in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $20.40.
Shares of NASDAQ GLMD opened at $6.00 on Tuesday. Galmed Pharmaceuticals has a fifty-two week low of $3.61 and a fifty-two week high of $12.22.
Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. research analysts anticipate that Galmed Pharmaceuticals will post -0.77 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Deutsche Bank AG bought a new position in shares of Galmed Pharmaceuticals in the 4th quarter valued at $246,000. Renaissance Technologies LLC bought a new position in shares of Galmed Pharmaceuticals in the 4th quarter valued at $345,000. J. Goldman & Co LP bought a new position in shares of Galmed Pharmaceuticals in the 4th quarter valued at $569,000. Sphera Funds Management LTD. bought a new position in shares of Galmed Pharmaceuticals in the 4th quarter valued at $2,164,000. Finally, Park West Asset Management LLC increased its stake in shares of Galmed Pharmaceuticals by 4.4% in the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after purchasing an additional 12,347 shares during the last quarter. Institutional investors own 18.86% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Maxim Group Reiterates $14.00 Price Target for Galmed Pharmaceuticals (GLMD)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/maxim-group-reiterates-14-00-price-target-for-galmed-pharmaceuticals-glmd.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.